Alterity Therapeutics Limited

NasdaqCM:ATHE Stock Report

Market Cap: US$70.0m

Alterity Therapeutics Management

Management criteria checks 2/4

Alterity Therapeutics' CEO is David Stamler, appointed in Jan 2021, has a tenure of 5.33 years. total yearly compensation is A$1.45M, comprised of 59.1% salary and 40.9% bonuses, including company stock and options. directly owns 0.84% of the company’s shares, worth $590.06K. The average tenure of the management team and the board of directors is 14.3 years and 14.8 years respectively.

Key information

David Stamler

Chief executive officer

AU$1.5m

Total compensation

CEO salary percentage59.09%
CEO tenure5.3yrs
CEO ownership0.8%
Management average tenure14.3yrs
Board average tenure14.8yrs

Recent management updates

Recent updates

Seeking Alpha • Aug 25

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Alterity Therapeutics (NASDAQ:ATHE) said its phase 2 trial of ATH434 to treat patients with Multiple System Atrophy (MSA) was open for enrolment in the U.K. "In a short period of time we have now commenced enrolment in our second region, and we look forward to broadening our reach over the next several months," said Alterity CEO David Stamler. In July, the company had said it dosed the first patient in New Zealand in the phase 2 study. The trial is expected to enroll ~60 adult patients who will either receive one of two dose levels of ATH434 or placebo for one year. MSA is a rare disorder of the nervous system which causes gradual damage to nerve cells in the brain and can affect  breathing, digestion and bladder control.
Seeking Alpha • Jul 06

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Alterity Therapeutics (NASDAQ:ATHE) said the first patient was dosed in a a phase 2 trial of ATH434 in Multiple System Atrophy (MSA) MSA is a rare disorder of the nervous system which causes gradual damage to nerve cells in the brain and can affect  breathing, digestion and bladder control. The trial is expected to enroll ~60 adult patients who will either receive one of two doses of ATH434 or placebo for one year.
Seeking Alpha • Sep 16

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

Alterity has been granted notice of allowance by USPTO for a new group of iron chaperones that redistribute excess iron in neurodegenerative diseases. The Company’s iron chaperone technology has decent potential. The Company’s ATH434 is a promising candidate with initial focus on MSA.

CEO Compensation Analysis

How has David Stamler's remuneration changed compared to Alterity Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-AU$15m

Sep 30 2025n/an/a

-AU$13m

Jun 30 2025AU$1mAU$859k

-AU$12m

Mar 31 2025n/an/a

-AU$16m

Dec 31 2024n/an/a

-AU$20m

Sep 30 2024n/an/a

-AU$19m

Jun 30 2024AU$1mAU$717k

-AU$19m

Mar 31 2024n/an/a

-AU$16m

Dec 31 2023n/an/a

-AU$12m

Sep 30 2023n/an/a

-AU$13m

Jun 30 2023AU$2mAU$731k

-AU$14m

Mar 31 2023n/an/a

-AU$14m

Dec 31 2022n/an/a

-AU$14m

Sep 30 2022n/an/a

-AU$14m

Jun 30 2022AU$2mAU$658k

-AU$13m

Mar 31 2022n/an/a

-AU$13m

Dec 31 2021n/an/a

-AU$13m

Sep 30 2021n/an/a

-AU$14m

Jun 30 2021AU$979kAU$606k

-AU$15m

Mar 31 2021n/an/a

-AU$16m

Dec 31 2020n/an/a

-AU$16m

Sep 30 2020n/an/a

-AU$15m

Jun 30 2020AU$625kAU$625k

-AU$13m

Mar 31 2020n/an/a

-AU$13m

Dec 31 2019n/an/a

-AU$13m

Sep 30 2019n/an/a

-AU$12m

Jun 30 2019AU$548kAU$548k

-AU$12m

Compensation vs Market: David's total compensation ($USD1.04M) is above average for companies of similar size in the US market ($USD649.34K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Stamler (64 yo)

5.3yrs
Tenure
AU$1,453,644
Compensation

Dr. David A. Stamler, M.D., serves as Chief Executive Officer at Alterity Therapeutics Limited since January 07, 2021 and serves as its Director since November 21, 2025. Dr. Stamler had been the Chief Medi...

Leadership Team

NamePositionTenureCompensationOwnership
David Stamler
CEO & Director5.3yrsAU$1.45m0.84%
$ 590.1k
Abby Macnish Niven
CFO & Company Secretary1.7yrsno datano data
Rudolph Emile Tanzi
Chief Scientific Advisor and Member of Research & Development Advisory Board14.3yrsno datano data
Steven Targum
Chief Medical Advisor19.2yrsno datano data
Robert Cherny
Head of Research19.1yrsno datano data
14.3yrs
Average Tenure
64yo
Average Age

Experienced Management: ATHE's management team is seasoned and experienced (14.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Stamler
CEO & Directorless than a yearAU$1.45m0.84%
$ 590.1k
Rudolph Emile Tanzi
Chief Scientific Advisor and Member of Research & Development Advisory Board19.2yrsno datano data
Colin Masters
Member of Research & Development Advisory Board19.2yrsAU$241.36kno data
Peter Marks
Non-Executive Independent Director20.8yrsAU$152.39k0.083%
$ 57.9k
Lawrence Gozlan
Non-Executive Director14.8yrsAU$207.31k0.042%
$ 29.3k
Ira Shoulson
Chairman of Research & Development Advisory Boardno dataAU$78.76kno data
Ann Cunningham
Independent Non-Executive Directorless than a yearno datano data
Julian Babarczy
Non-Executive Chairless than a yearno datano data
14.8yrs
Average Tenure
66yo
Average Age

Experienced Board: ATHE's board of directors are seasoned and experienced ( 14.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/21 05:09
End of Day Share Price 2026/05/21 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alterity Therapeutics Limited is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
George ZavoicoB. Riley Securities, Inc.
Madeleine WilliamsCanaccord Genuity
Aydin HuseynovLadenburg Thalmann & Company